AstraZeneca's Enhertu trial demonstrates unprecedented improvements in breast cancer treatment, particularly for HER2 low cases.

AstraZeneca's Enhertu trial shows "unprecedented" improvements in breast cancer treatment, particularly for HER2 low and ultra-low cases. The antibody-drug conjugate significantly reduces the risk of disease progression or death, potentially treating eight out of ten women with metastatic breast cancer. Enhertu is currently approved for second-line treatment of HER2 positive and HER2 low breast cancer, but the trial indicates its potential expansion into earlier lines of therapy.